Skip to main content

HUM Humana Inc.

Healthcare

quality needs a look, premium valuation.

Quality
Weak
Valuation
Expensive
Key signals
52-week adjusted-price high Top-quintile 6-month momentum Filed revenue acceleration
384.72
384.72 Close (USD) Loading candles…

Is Humana Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 37th percentile. TTM ROE is about 6.1%.

  • Valuation is expensive. TTM P/E is in the 88th percentile, above most peers.

  • Recent volatility is moderate. 60-day annualized volatility is near the 37th percentile. Average 20-day dollar volume is about $376.3M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Humana Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

24 historical occurrences (since 2017-03-07)
Average forward return after 52-week adjusted-price high。20-day: Win 39.1%, Sample 23, Median -0.9%, Excess -0.29%, Beat mkt rate 52.2%；60-day: Win 68.2%, Sample 22, Median +4.38%, Excess +1.41%, Beat mkt rate 63.6%；120-day: Win 61.9%, Sample 21, Median +6.24%, Excess -0.38%, Beat mkt rate 57.1%

120 days after: historical avg +4.1%

20-day -0.73%
60-day +3.44%
120-day +4.1%
20-day
60-day
120-day
Win
39.1%
68.2%
61.9%
Sample
23
22
21
Median
-0.9%
+4.38%
+6.24%
Excess
-0.29%
+1.41%
-0.38%
Beat mkt rate
52.2%
63.6%
57.1%

Over 21 occurrences, 120-day forward avg gained 4.1%, lagged the market by 0.38 pts; win rate 61.9%.

Top-quintile 6-month momentum

Active · now 97.88135593220339%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

19 historical occurrences (since 2017-01-09)
Average forward return after Top-quintile 6-month momentum。20-day: Win 52.6%, Sample 19, Median +0.59%, Excess +2.99%, Beat mkt rate 63.2%；60-day: Win 73.7%, Sample 19, Median +6.87%, Excess +3.63%, Beat mkt rate 68.4%；120-day: Win 72.2%, Sample 18, Median +13.41%, Excess +1.28%, Beat mkt rate 61.1%

120 days after: historical avg +8.15%

20-day +3.67%
60-day +8.41%
120-day +8.15%
20-day
60-day
120-day
Win
52.6%
73.7%
72.2%
Sample
19
19
18
Median
+0.59%
+6.87%
+13.41%
Excess
+2.99%
+3.63%
+1.28%
Beat mkt rate
63.2%
68.4%
61.1%

Over 18 occurrences, 120-day forward avg gained 8.15%, beat the market by 1.28 pts; win rate 72.2%.

Filed revenue acceleration

Active · now 14.084249388834369%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2019-07-31)
Average forward return after Filed revenue acceleration。20-day: Win 53.8%, Sample 13, Median +0.3%, Excess +0.44%, Beat mkt rate 46.2%；60-day: Win 61.5%, Sample 13, Median +5.64%, Excess +7.24%, Beat mkt rate 53.8%；120-day: Win 75%, Sample 12, Median +10.86%, Excess +5.49%, Beat mkt rate 50%

120 days after: historical avg +13.5%

20-day +0.37%
60-day +10.19%
120-day +13.5%
20-day
60-day
120-day
Win
53.8%
61.5%
75%
Sample
13
13
12
Median
+0.3%
+5.64%
+10.86%
Excess
+0.44%
+7.24%
+5.49%
Beat mkt rate
46.2%
53.8%
50%

Over 12 occurrences, 120-day forward avg gained 13.5%, beat the market by 5.49 pts; win rate 75%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 285+9.5% +5.7% 73.7% -13.2%
20-40 381-3% +0.2% 50.4% -18.8%
40-60 243+0.9% +2.1% 54.3% -13.3%
60-80 309-6.3% -6.1% 40.1% -15.4%
80-100 You are here196-18.6% -19.9% 11.2% -32.8%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 41.15, placing it in the 96.2 own-history percentile, inside the 80-100 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
-1.2%
Win rate 57.4% Excess -15.2%
230d
-3.7%
Win rate 56.5% Excess -7.5%
333d
Now
-11.6%
Win rate 14.8% Excess -18%
237d
60-day momentum down
+16.1%
Win rate 72.7% Excess +4.4%
352d
+7.6%
Win rate 71.9% Excess +6.4%
153d
-0.7%
Win rate 36.2% Excess -7.7%
229d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 237 historical days, 120-day forward avg declined 11.6%, win rate 14.8%, lagged the market by 18%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,524 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.9% positive-return rate, and +2.77 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

21 times historically; 60-day forward avg -1.08%, win rate 57.1%, beating the market by -5.81 pts on average.

Continue researching Humana Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.